Literature DB >> 25388274

An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials.

Valérie Garès1, Sandrine Andrieu, Jean-François Dupuy, Nicolas Savy.   

Abstract

The logrank test is optimal for testing the equality of survival distributions against a proportional hazards alternative. Under a late effects alternative, it is no longer appropriate, and one may turn to Fleming-Harrington's class of weighted logrank tests instead. In some settings, such as in preventive clinical trials where the statistical analysis has to be designed before the trial begins, it can be difficult to choose a priori between the logrank and Fleming-Harrington tests. A solution to this issue is provided. A decision rule is constructed for the problem of testing the equality of two survival distributions when the expected alternative may be one of the proportional hazards and late effects. A formula for computing the necessary sample size is obtained for this decision rule. A comprehensive simulation study is conducted to assess finite sample properties of the proposed test statistic. The proposed test improves both the logrank test and Fleming-Harrington's test for late effects. Finally, the methodology is illustrated on a data set in the field of prevention of Alzheimer's disease.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical trials; hypothesis testing; maximum weighted tests; survival data

Mesh:

Substances:

Year:  2014        PMID: 25388274     DOI: 10.1002/sim.6366

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761.

Authors:  B Scherrer; S Andrieu; P J Ousset; G Berrut; J F Dartigues; B Dubois; F Pasquier; F Piette; P Robert; J Touchon; P Garnier; H Mathiex-Fortunet; B Vellas
Journal:  J Nutr Health Aging       Date:  2015-12       Impact factor: 4.075

2.  Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations.

Authors:  Lu Tian; Haoda Fu; Stephen J Ruberg; Hajime Uno; Lee-Jen Wei
Journal:  Biometrics       Date:  2017-09-12       Impact factor: 2.571

3.  Second monotherapy in childhood absence epilepsy.

Authors:  Avital Cnaan; Shlomo Shinnar; Ravindra Arya; Peter C Adamson; Peggy O Clark; Dennis Dlugos; Deborah G Hirtz; David Masur; Tracy A Glauser
Journal:  Neurology       Date:  2016-12-16       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.